Gentian Diagnostics ASA
Develops and markets in vitro diagnostic reagents for human and veterinary use.
GENT | OL
Overview
Corporate Details
- ISIN(s):
- NO0010748866
- LEI:
- 5967007LIEEXZXHNM861
- Country:
- Norway
- Address:
- Bjørnåsveien 5, 1596 Moss
- Website:
- https://www.gentian.com/
- Sector:
- Manufacturing
Description
Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-08-27 12:58 |
STUDY CONFIRMS SIGNIFICANTLY ELEVATED LEVELS OF CALPROTECTIN IN PATIENTS WITH S…
|
English | 2.5 KB | ||
| 2020-08-27 09:53 |
Primary insider notification - Korr
|
English | 1.3 KB | ||
| 2020-08-27 09:10 |
Primary insider notification
|
English | 1.2 KB | ||
| 2020-08-21 06:00 |
2nd quarter and first half 2020 report
|
English | 1.2 MB | ||
| 2020-08-21 06:00 |
2nd quarter and first half 2020 report
|
English | 2.1 MB | ||
| 2020-08-21 06:00 |
2nd quarter and first half 2020 report
|
English | 1.4 KB | ||
| 2020-08-14 07:49 |
Presentation of second quarter and first half results for 2020 for Gentian Diag…
|
English | 798 bytes | ||
| 2020-07-03 06:23 |
Gentian awarded up to NOK 8.0 million funding to develop a novel high-throughpu…
|
English | 2.0 KB | ||
| 2020-06-16 12:39 |
Release of BÜHLMANN fPELA® turbo
|
English | 2.2 KB | ||
| 2020-05-14 10:37 |
Minutes of Annual General Meeting
|
English | 4.4 MB | ||
| 2020-05-14 10:37 |
Minutes of Annual General Meeting
|
English | 661 bytes | ||
| 2020-04-29 10:46 |
Notice of Annual General Meeting
|
English | 131.3 KB | ||
| 2020-04-29 10:46 |
Notice of Annual General Meeting
|
English | 1.1 KB | ||
| 2020-04-24 07:31 |
2019 Annual Report
|
English | 4.2 MB | ||
| 2020-04-24 07:31 |
2019 Annual Report
|
English | 771 bytes |
Automate Your Workflow. Get a real-time feed of all Gentian Diagnostics ASA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Gentian Diagnostics ASA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Gentian Diagnostics ASA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
